Se connecter Inscription gratuite

Edesa Biotech BPA estimée Q/Q

Quel est le BPA estimée Q/Q de Edesa Biotech?

Le BPA estimée Q/Q de Edesa Biotech, Inc. est 44.44%

Quelle est la définition de BPA estimée Q/Q?



Le taux de croissance prospectif du BPA trimestriel, d'une année à l'autre , correspond à l'augmentation estimée du BPA d'une entreprise pour le prochain trimestre par rapport à la performance d'un trimestre précédent.

The prospective EPS growth rate is a predicted estimate of the earnings per share growth rate towards the current quarter and expressed as a percentage compared to the respective past quarter. The estimated earnings per share growth rate is an important factor for judging a company's value. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

BPA estimée Q/Q des entreprises dans Health Care secteur sur NASDAQ par rapport à Edesa Biotech

Que fait Edesa Biotech?

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Entreprises avec bpa estimée q/q similaire à Edesa Biotech